Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
0.8835
+0.0319 (3.75%)
At close: Dec 5, 2025, 4:00 PM EST
0.8835
0.00 (0.00%)
After-hours: Dec 5, 2025, 8:00 PM EST
Oragenics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
3.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 37.65K | -93.87K | -71.37% |
| Dec 31, 2022 | 131.52K | 44.53K | 51.20% |
| Dec 31, 2021 | 86.99K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 939.93K | -92.31K | -8.94% |
| Dec 31, 2013 | 1.03M | -299.53K | -22.49% |
| Dec 31, 2012 | 1.33M | -112.68K | -7.80% |
| Dec 31, 2011 | 1.44M | 135.54K | 10.35% |
| Dec 31, 2010 | 1.31M | 667.63K | 104.11% |
| Dec 31, 2009 | 641.29K | 407.75K | 174.59% |
| Dec 31, 2008 | 233.54K | 100.45K | 75.48% |
| Dec 31, 2007 | 133.09K | 66.91K | 101.11% |
| Dec 31, 2006 | 66.18K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
OGEN News
- 23 days ago - Oragenics Q3 2025 Shareholder Update - Business Wire
- 6 weeks ago - Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency - Business Wire
- 2 months ago - Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development - Business Wire
- 4 months ago - Oragenics Q2 2025 Shareholder Update - GlobeNewsWire
- 5 months ago - Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development - GlobeNewsWire
- 5 months ago - Oragenics Completes Approximately $16.5 Million Offering - GlobeNewsWire
- 5 months ago - Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants - GlobeNewsWire
- 7 months ago - Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia - GlobeNewsWire